Clinical Trials Logo

HER2 Positive clinical trials

View clinical trials related to HER2 Positive.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06254807 Recruiting - HER2-positive Clinical Trials

CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

Start date: January 8, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human open-label study to evaluate the safety and tolerability, and manufacturing feasibility of anti-HER2 CAR-monocytes (CT-0525) in participants with locally advanced (unresectable) or metastatic solid tumors overexpressing HER2 whose disease has progressed on standard approved therapies.

NCT ID: NCT05135715 Recruiting - Advanced Melanoma Clinical Trials

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Start date: April 19, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase IIa, single-arm, multicentre, open-label clinical trial aims to evaluate the effectiveness and safety of RC48-ADC in the treatment of HER2 Variant (Mutation, Amplification, Overexpression) advanced melanoma.

NCT ID: NCT04152057 Recruiting - Breast Cancer Clinical Trials

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

Start date: November 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study was designed to evaluate the efficacy and safety of pyrotinib combined with albumin paclitaxel and trastuzumab in the treatment of Her2-positive early or locally advanced breast cancer, and to explore RCB scores and TILs expression and other related molecular markers for pyrrole the efficacy of the treatment with pyrotinib.